{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:30Z","timestamp":1791223770710,"version":"4.1.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We examined the susceptibilities to amphotericin B, flucytosine, fluconazole, posaconazole, ravuconazole, voriconazole, and caspofungin of 601 invasive isolates of\n            <jats:italic>Candida glabrata<\/jats:italic>\n            and grouped the isolates by geographic location: North America (331 isolates), Latin America (58 isolates), Europe (135 isolates), and Asia-Pacific (77 isolates). Caspofungin (MIC at which 90% of isolates tested are susceptible [MIC\n            <jats:sub>90<\/jats:sub>\n            ], 0.12 \u03bcg\/ml; 100% of strains are susceptible [S] at a MIC of \u22641 \u03bcg\/ml) and flucytosine (MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.12 \u03bcg\/ml; 99.2% S) were the most active agents in all geographic regions. Fluconazole susceptibility was highest in the Asia-Pacific region (80.5% S, 3.9% resistant [R]) and lowest in North America (64% S, 10.3% R) and Latin America (62.1% S, 3.4% R). The extended-spectrum triazoles were most active in the Asia-Pacific region (90 to 96.1% S) and least active in North America (82.5 to 90.3% S). All 46 isolates that were resistant to fluconazole were susceptible to caspofungin (MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.06 \u03bcg\/ml) and flucytosine (MIC\n            <jats:sub>90<\/jats:sub>\n            , 0.12 \u03bcg\/ml) and exhibited variable cross-resistance to posaconazole, ravuconazole, and voriconazole.\n          <\/jats:p>","DOI":"10.1128\/jcm.42.7.3142-3146.2004","type":"journal-article","created":{"date-parts":[[2004,7,8]],"date-time":"2004-07-08T18:19:31Z","timestamp":1089310771000},"page":"3142-3146","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":157,"title":["Geographic Variation in the Susceptibilities of Invasive Isolates of\n            <i>Candida glabrata<\/i>\n            to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002"],"prefix":"10.1128","volume":"42","author":[{"given":"M. A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"Departments of Pathology"},{"name":"Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Messer","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boyken","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tendolkar","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Hollis","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Diekema","sequence":"additional","affiliation":[{"name":"Departments of Pathology"},{"name":"Medicine, Roy J. and Lucille A. Carver College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"1131","volume":"7","year":"1998","unstructured":"Abi Said, D., and E. Anaissie. 1998. Epidemiology of non-albicans Candida spp. Baillieres Clin. Infect. Dis.7:1131-1133.","journal-title":"Baillieres Clin. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1179-1186.2003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3165-3169.2003"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1193-1199.2003"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.9.3489-3492.2002"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg275"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.08.002"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1054\/drup.1998.0059"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.1.80"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199907000-00002"},{"key":"e_1_3_2_12_2","unstructured":"Hazen K. C. and S. A. Howell. 2003. Candida Cryptococcus and other yeasts of medical importance p. 1693-1711. In P. R. Murray E. J. Baron J. H. Jorgensen M. A. Pfaller and R. H. Yolken (ed.) Manual of clinical microbiology 8th ed. ASM Press Washington D.C."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/367933"},{"key":"e_1_3_2_14_2","first-page":"139","volume":"42","year":"1997","unstructured":"Krcmery, V. Jr. 1997. Breakthrough fungemia during therapy with amphotericin B. Chemotherapy42:139-140.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.3.373"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2001.1151"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000239322"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960000325"},{"key":"e_1_3_2_19_2","unstructured":"National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2 2nd ed. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/514193"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3149-3154.2003"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00120-5"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.9.3254-3259.2001"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2862-2864.2001"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.10.3551-3557.2002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1723-1727.2002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.5.2176-2179.2003"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1470-9465.2004.t01-1-00844.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.008"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.7.3117-3119.2004"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0908.030069"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.2.619-622.2003"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/313749"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.575"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2002.00446.x"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3268-3272.2002"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00181-0"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.1.40"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2002.1261"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg393"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/342300"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01591361"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.1847"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.42.7.3142-3146.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.42.7.3142-3146.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T03:16:57Z","timestamp":1646450217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.42.7.3142-3146.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1128\/JCM.42.7.3142-3146.2004"],"URL":"https:\/\/doi.org\/10.1128\/jcm.42.7.3142-3146.2004","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]},"assertion":[{"value":"2004-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}